Business Context and Reporting Period
MacroGenics, Inc. filed this Form 8-K on September 17, 2015, reporting an event dated September 15, 2015. The filing details the entry into a material definitive agreement with the National Institute of Allergy and Infectious Diseases (NIAID).
Key Financial Metrics
This filing does not report historical revenue, profit, cash flow, margins, debt, or liquidity metrics. The primary financial data relates to the new contract terms:
- Base Contract Value: $7.5 million
- Option Value: Up to $17 million
- Total Potential Value: Up to $24.5 million
- Performance Period: September 15, 2015, through September 14, 2022
Material Changes
The material change is the execution of a government contract to develop therapeutic product candidates DART-1 and DART-2. These candidates utilize the company's proprietary Dual-Affinity Re-Targeting (DART) technology and are intended for Phase 1/2 Clinical Trials to deplete HIV-infected cells in combination with latency reversing treatments.
Outlook, Risks, and Contingencies
Outlook: The agreement supports development through the Investigational New Drug (IND) application filing with the FDA. Future funding is contingent upon NIAID exercising options.
Risks and Contingencies: The contract includes standard government provisions allowing NIAID to terminate the agreement or order the cessation of work at its discretion. Revenue recognition is dependent on the exercise of options and successful performance milestones.
Investor Verification Checklist
- Verify the specific milestones required to trigger the $17 million in option payments.
- Confirm the current development status of DART-1 and DART-2 relative to the Phase 1/2 trial timeline.
- Review the company's cash burn rate to assess the impact of the $7.5 million base funding on liquidity.
- Monitor for any future 8-K filings regarding the exercise or non-exercise of NIAID options.